Diphtheria, Pertussis, and Tetanus (DTP) Vaccine, also known as the Triple antigen, is the most commonly used vaccine in countries with poor health infrastructure.
Diphtheria, Pertussis, and Tetanus (DTP) Vaccine, also known as the Triple antigen, is the most commonly used vaccine in countries with poor health infrastructure. It is an intramuscular vaccine that is applied to the babies at ages 1.5 months, 2.5 months and at 3.5 months in order to offer protection and immunity against three deadly diseases. The second dose of DPT vaccine is given when the child grows up to 1.5 years of age. Also, children more than 10 years of age are given the Tdap vaccine as a 1-shot dose.
In addition, adults who want to boost their immunity or those susceptible to diphtheria can go for the DTP vaccine. Similarly, pregnant women must take a DTP vaccine dose in the final stage of pregnancy so that the newborn baby remains protected against the diseases.
Download Sample Report at: https://www.alliedmarketresearch.com/request-sample/3810
The global DTP vaccines market is expected to grow at a steady rate during the forecast period, owing to growth in awareness among people about the advantages of DTP vaccines globally, especially in developing countries. Moreover, rise in initiatives by pharma companies to enhance vaccine R&D is anticipated to supplement the DTP vaccines market growth. In addition, collaboration among the vaccine market stakeholders to employ combination of all available product development strategies is important to increase the overall success to make vaccination accessible across the globe.
The key factors such as rise in demand for DTaP vaccine and growth in adoption of pertussis vaccine around the globe drives the growth of DTaP segment. Furthermore, high efficacy and rise in demand in developing regions is expected to drive the market during the forecast period. In addition, introduction of new combination of vaccines with DTaP further provides opportunities for the market players.
DTP vaccine is extremely important as it protects you against diphtheria, tetanus and pertussis diseases. If not taken vaccines, pertussis, referred as whooping cough, can make it hard for children to breathe and could cause serious complications. Diphtheria toxin also causes breathing difficulties while also damages the liver & kidney. The tetanus bacteria, usually found in the soil, enters human body through abrasions or cuts and can block heart function and cause difficulty in breathing.
According to a report published by Allied Market Research, the global diphtheria, pertussis, and tetanus vaccines market size is registered to reach $7.05 billion with a considerable CAGR from 2020 to 2027. North America is currently witnessing the highest market share. The Asia-Pacific region, at the same time, is expected to manifest the fastest CAGR. Factors such as rise in population, surge in demand for DTP vaccines, and increase in awareness of new technologies are boosting the growth of the market across various regions.
By end user, in 2019, the hospitals segment dominated the DTP vaccines market, with large share due to faster availability of these vaccines in hospitals and shorter duration of procedure. Hospitals are the integral part of the healthcare sector, which act as the major source for revenue generation and aid in research and innovation.
Moreover, rise in number of cases, especially in the late spring & early summer, augments the growth of the global DTP vaccines market. Meanwhile, government and non-government initiatives for the development of DTP vaccines are exponentially impacting the growth of the market. In a nutshell, the global DTP vaccines market has lucrative opportunities to gather immense growth in the years to come.